Antibody Drug Conjugate Market Size, Share, Growth, Latest Trend, To Witness A Significant Growth During Forecast 2023

The Latest Data Has Been Presented In The Study On The Revenue Numbers, Product Details, And Sales Of The Major Firms. In Addition To This, The Information Also Comprises The Breakdown Of The Revenue For The Global Antibody Drug Conjugate Market

Market Insights:

The Global Antibody Drug Conjugate (ADC) Market Is Projected To Witness A Stupendous Growth At A Notable 19% CAGR Over The Predicted Years (2017-2023).

ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.

The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers. The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.

Offering Free Sample Report Earlier Buyer @

Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.

Market Competition:

The market is quite open and encourages innovation to simplify complex production methods. For instance, WuXi Biologics started construction of a research & development and manufacturing center that would showcase state-of-the-art technologies and eyes a global expansion. Also, ADC Biotechnology has successfully secured substantial funding from Downing LLP, a London-based investment management firm. Sanofi, in collaboration with Meditope Biosciences, has developed a bioconjugation platform to develop better medicines. 

Some major players in the global antibody-drug conjugate market include Industry Trends:

SeattleGenetics (US)
Immunomedics (US)
Roche Holding AG (Switzerland)
Antikor (UK)
Genentech (US)
Concortis Biotherapeutics (US) and others…
Industry Developments:

In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.

Market Segmentation:

By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.

By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.

By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.

By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others. 

Regional Analysis:

By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.

Get Complete Report Details with Detail Tables and Figures @

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

 MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Address: Contact:, , Market Research Future, , Office No. 528, Amanora Chambers, , Magarpatta Road, Hadapsar,, , Pune - 411028, , Maharashtra, India, , +1 646 845 9312, , Email:
Phone: 646845931

Release ID: 88908700